Incarcerated people are disproportionately impacted by the hepatitis C virus (HCV). The purpose of this needs assessment was to characterize the population of incarcerated people with anti-HCV antibodies in one county jail system and assess the readiness of medical staff and patients for scaling up jail-based treatment. Logistic regression was used to identify factors associated with new HCV diagnoses in a retrospective cohort of patients completing HCV antibody and viral load testing between 2016 and 2021. Semistructured interviews were also conducted with 31 incarcerated people and 6 jail health services staff and thematically analyzed to identify barriers to and facilitators of jail-based HCV treatment. Of 6,282 people completing HCV antibody testing between 2016 and 2021, 79 (1.3%) were incarcerated long enough with a confirmed, active HCV infection to be cured, but were not. Of the incarcerated interviewees, 36% (8 people) preferred jail-based treatment of HCV. Jail health services staff were universally ready and willing to provide treatment in jail, should the budget allow. Many incarcerated people can be successfully diagnosed and cured of HCV in jail, and both incarcerated people and those who provide their health care desire jail-based treatment.
AbeC. M., AguwaM., ZhaoM., SullivanJ., PorsaE., & NijhawanA. E. (2019). Hepatitis C virus infection in the Dallas County Jail: Implications for screening, prevention, and linkage to care. Public Health Reports, 134(6), 626–633. 10.1177/0033354919874081
2.
AkiyamaM. J., ColumbusD., MacDonaldR., JordanA. O., SchwartzJ., LitwinA. H., EckhardtB., & CarmodyE. (2019). Linkage to hepatitis C care after incarceration in jail: A prospective, single arm clinical trial. BMC Infect Dis, 19(1), 703. 10.1186/s12879-019-4344-1
3.
AkiyamaM. J., KabaF., RosnerZ., AlperH., KopolowA., LitwinA. H., VentersH., & MacDonaldR. (2017). Correlates of hepatitis C virus infection in the targeted testing program of the New York City jail system: Epidemiologic patterns and priorities for action. Public Health Reports 132(1), 41–47. 10.1177/0033354916679367
4.
BorkanJ. M. (2022). Immersion–crystallization: A valuable analytic tool for healthcare research. Family Practice, 39(4), 785–789. 10.1093/fampra/cmab158
ChanJ., KabaF., SchwartzJ., BocourA., AkiyamaM. J., RosnerZ., WintersA., YangP., & MacDonaldR. (2020). The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014–2017. EClinicalMedicine, 27, 100567. 10.1016/j.eclinm.2020.100567
7.
ChanJ., SchwartzJ., KabaF., BocourA., AkiyamaM. J., HobstetterL., RosnerZ., WintersA., YangP., & MacDonaldR. (2020). Outcomes of hepatitis C virus treatment in the New York City jail population: Successes and challenges facing scale up of care. Open Forum Infectious Diseases, 7(7), ofaa263. 10.1093/ofid/ofaa263
8.
Clemenzi-Allen, A.A. (2023). Demographics, HCV status, and jail intake and discharge date of people seen by Jail Health Services, from the Jail Information Management (JIM) medical records system from January 2016 - September 2021 [Unpublished raw data]. San Francisco Jail Health Services.
9.
DanielsA. M., & StuddertD. M. (2020). Hepatitis C treatment in prisons—Incarcerated people’s uncertain right to direct-acting antiviral therapy. The New England Journal of Medicine, 383(7), 611–613. 10.1056/NEJMp2004438
10.
EckhardtB., Mateu-GelabertP., Aponte-MelendezY., FongC., KapadiaS., SmithM., EdlinB. R., & MarksK. M. (2022). Accessible hepatitis C care for people who inject drugs: A randomized clinical trial. JAMA Internal Medicine, 182(5), 494–502. 10.1001/jamainternmed.2022.0170
11.
FraserH., VellozziC., HoergerT. J., EvansJ. L., KralA. H., HavensJ., YoungA. M., StoneJ., HandanagicS., HaririS., BarbosaC., HickmanM., LeibA., MartinN. K., NerlanderL., RaymondH. F., PageK., ZibbellJ., WardJ. W., & VickermanP. (2019). Scaling up hepatitis C prevention and treatment interventions for achieving elimination in the United States: A rural and urban comparison. American Journal of Epidemiology, 188(8), 1539–1551. 10.1093/aje/kwz097
GrebelyJ., DoreG. J., MorinS., RockstrohJ. K., & KleinM. B. (2017). Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there? Journal of the International AIDS Society, 20(1), 22146. 10.7448/ias.20.1.22146
14.
KamatS., KondapalliS., SyedS., PriceG., DaniasG., GorbenkoK., CantorJ., ValeraP., ShahA. K., & AkiyamaM. J. (2023). Access to hepatitis C treatment during and after Incarceration in New Jersey, United States: A qualitative study. Life, 13(4), 1033. 10.3390/life13041033
15.
KronfliN., MambroA., RibackL. R., Ortiz-ParedesD., DussaultC., ChalifouxS., Del BalsoL., PetropoulosA., LimM., HalavrezosA., SebastianiG., KleinM. B., LeboucheB., CoxJ., & AkiyamaM. J. (2024). Perceived patient navigator services and characteristics to address barriers to linkage to hepatitis C care among people released from provincial prison in Quebec, Canada. The International Journal on Drug Policy, 133, 104624. 10.1016/j.drugpo.2024.104624
16.
LyK. N., HughesE. M., JilesR. B., & HolmbergS. D. (2016). Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clinical Infectious Diseases, 62(10), 1287–1288. 10.1093/cid/ciw111
17.
ManerM., OmoriM., Brinkley-RubinsteinL., BeckwithC. G., & NowotnyK. (2022). Infectious disease surveillance in U.S. jails: Findings from a national survey. PLOS One, 17(8), e0272374. 10.1371/journal.pone.0272374
18.
MatucciT., RiccardiN., OcchineriS., PontarelliA., TiseoG., FalconeM., PuciM., SaderiL., & SotgiuG. (2023). Treatment of latent tuberculosis infection in incarcerated people: A systematic review. Clinical Microbiology and Infection, 29(6), 714–721. 10.1016/j.cmi.2023.02.016
19.
MirzazadehA., FacenteS. N., BurkK., KahnJ. G., & MorrisM. D. (2022). Hepatitis C mortality trends in San Francisco: Can we reach elimination targets? Annals of Epidemiology, 65, 59–64. 10.1016/j.annepidem.2021.10.004
NortonB. L., VoilsC. I., TimberlakeS. H., HeckerE. J., GoswamiN. D., HuffmanK. M., LandgrafA., NaggieS., & StoutJ. E. (2014). Community-based HCV screening: Knowledge and attitudes in a high risk urban population. BMC Infectious Diseases, 14(1), 74. 10.1186/1471-2334-14-74
22.
QureshiN., TadesseM., TranN., & HendersonS. (2021). Establishing an epidemiologic profile of hepatitis C virus infection at the Los Angeles County Jail. Public Health Reports, 136(6), 726–735. 10.1177/0033354920988610
23.
R Core Team. (2018). R: A language and environment for statistical computing. https://www.R-project.org/
24.
SaberiP., CaswellN. H., JamisonR., EstesM., & TulskyJ. P. (2012). Directly observed versus self-administered antiretroviral therapies: Preference of HIV-positive jailed inmates in San Francisco. Journal of Urban Health, 89(5), 794–801. 10.1007/s11524-012-9682-x
25.
SchillieS., WesterC., OsborneM., WesolowskiL., & RyersonA. B. (2020). CDC recommendations for hepatitis C screening among adults - United States, 2020. Morbidity and Mortality Weekly Report, 69(2), 1–17. 10.15585/mmwr.rr6902a1
26.
ScottN., McBrydeE., VickermanP., MartinN. K., StoneJ., DrummerH., & HellardM. (2015). The role of a hepatitis C virus vaccine: Modelling the benefits alongside direct-acting antiviral treatments. BMC Medicine, 13, 198. 10.1186/s12916-015-0440-2
27.
SolomonL., FlynnC., MuckK., VertefeuilleJ. (2004). Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. Journal of Urban Health, 81(1), 25–37. 10.1093/jurban/jth085
28.
SpauldingA. C., ChhatwalJ., AdeeM. G., LawrenceR. T., BeckwithC. G., Von OehsenW. (2019). Funding hepatitis C treatment in correctional facilities by using a nominal pricing mechanism. Journal of Correctional Health Care, 25(1), 15–24. 10.1177/1078345818805770
29.
SpauldingA. C., RabeeahZ., Del Mar González-MontalvoM., AkiyamaM. J., BakerB. J., BauerH. M., GibsonB. R., NijhawanA. E., ParvezF., WanguZ., & ChanP. A. (2022). Prevalence and management of sexually transmitted infections in correctional settings: A systematic review. Clinical Infectious Diseases, 74(Suppl_2), S193–S217. 10.1093/cid/ciac122
30.
SufrinC., KramerC., TerplanM., FiscellaK., OlsonS., VoegtlineK., & LatkinC. (2023). Availability of medications for opioid use disorder in U.S. jails. Journal of General Internal Medicine, 38(6), 1573–1575. 10.1007/s11606-022-07812-x
31.
TatarM., KeeshinS. W., MailliardM., & WilsonF. A. (2020). Cost-effectiveness of universal and targeted hepatitis C virus screening in the United States. JAMA Network Open, 3(9), e2015756. 10.1001/jamanetworkopen.2020.15756
WiersemaJ., SchwartzJ., BocourA., JulianE., & ChanJ. (2024). Evaluation of a transitional patient navigation protocol for people living with hepatitis C virus in the New York City jail system. Journal of Health Care for the Poor and Underserved, 35(2), 516–531. 10.1353/hpu.2024.a928630
34.
Yoshida-CervantesM., HiltonJ. F., PrattL., AggarwalS., McDonaldJ., HalliwaillS., & LuetkemeyerA. (2018, July 23–27). Reaching underserved populations living with HCV: Pairing treatment with intensive navigation to improve adherence and completion of HCV treatment during and after incarceration in San Francisco jails [Poster presentation]. 22nd International AIDS Conference, Amsterdam, Netherlands.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
